Genmab A/S (GMAB) Stock Forecast & Price Target

$27.52

-0.17 (-0.61%)

(As of 09/6/2024 ET)

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 13 Analyst Ratings

Based on 13 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 2 have given a sell rating, 3 have given a hold rating, and 8 have given a buy rating for GMAB.

Consensus Price Target

$45.80
66.42% Upside

High Forecast	$53.00
Average Forecast	$45.80
Low Forecast	$31.00

According to the 13 analysts' twelve-month price targets for Genmab A/S, the average price target is $45.80. The highest price target for GMAB is $53.00, while the lowest price target for GMAB is $31.00. The average price target represents a forecasted upside of 66.42% from the current price of $27.52.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	3 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	7 Hold rating(s)
Sell	2 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$45.80	$49.50	$49.25	$46.00
Forecasted Upside	66.42% Upside	76.94% Upside	66.72% Upside	17.11% Upside

Get Genmab A/S Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.

Ad Crypto 101 Media

Perfect Crypto Buying Opportunity for 50 Cents

When cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious Bank

Go here to get full details on this crypto now.

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Genmab A/S Stock vs. The Competition

Type	Genmab A/S	Medical Companies	S&P 500
Consensus Rating Score	2.46	2.77	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	66.42% Upside	1,207.57% Upside	11.36% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/4/2024	Morgan Stanley 3 of 5 stars		Reiterated Rating	Equal Weight	$31.00	+13.10%
8/27/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00	+82.75%
8/20/2024	JPMorgan Chase & Co. 3 of 5 stars		Reiterated Rating	Overweight ➝ Neutral
7/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Campbell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform
6/27/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$46.00 ➝ $47.00	+83.09%
6/4/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$50.00 ➝ $53.00	+83.84%
Get the Latest News and Ratings for GMAB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.
2/23/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$46.00 ➝ $48.00	+64.89%
1/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Sell
12/6/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy
11/10/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
11/8/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Buy
10/18/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform
10/12/2023	Nordea Equity Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
2/23/2023	Danske Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
2/6/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$33.00 ➝ $36.00	-5.91%
11/17/2022	AlphaValue Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce
11/15/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$43.00	-0.23%
11/14/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:15 PM ET.

GMAB Forecast - Frequently Asked Questions

What is Genmab A/S's forecast for 2024?: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $45.80, with a high forecast of $53.00 and a low forecast of $31.00.
Should I buy or sell Genmab A/S stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
Does Genmab A/S's stock price have much upside?: According to analysts, Genmab A/S's stock has a predicted upside of 65.49% based on their 12-month stock forecasts.
Has Genmab A/S been upgraded by Wall Street analysts recently?: Over the previous 90 days, Genmab A/S's stock had 1 upgrade by analysts.
What analysts cover Genmab A/S?: Genmab A/S has been rated by research analysts at BTIG Research, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, and Royal Bank of Canada in the past 90 days.
Do Wall Street analysts like Genmab A/S more than its competitors?: Analysts like Genmab A/S less than other "medical" companies. The consensus rating for Genmab A/S is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GMAB compares to other companies.